PRNewsWire
05 Nov 2025, 21:05 UTC · 45w ago
Verdict
Headline takes no side. We score JAZZ +1.00 across four claims — strongly bullish.
+1.00strongly bullish
More positive than 98% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Modeyso received FDA approval as the first and only treatment for recurrent H3 K27M-mutant DMG.
More positive than 91% of claims this week
The Zepzelca and atezolizumab combination was approved as maintenance therapy in first-line extensive small cell lung cancer (ES-SCLC).
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 84% of claims this week
Jazz Pharmaceuticals achieved its highest revenue quarter in company history in 3Q25, with total revenues increasing 7% year-over-year to $1.13 billion.
More positive than 76% of claims this week
Top-line data from the Phase 3 HERIZON-GEA-01 trial for zanidatamab is expected before the end of the year.
More positive than 64% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
The company reported its highest revenue quarter in history, grew total revenues by 7% year-over-year, and received new FDA approvals for Modeyso and Zepzelca.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
24/7 Wall Street
23h ago
+74.7%
Price agrees with the score
$239.72 vs $137.22 close before publication (Nov 5) · not market-adjusted
JAZZ chart →
